GlobeNewswire·Aug 13, 2026, 4:05 PM ET

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Dosed first participants in the Phase 1a expansion cohort for RT-114 with additional data expected by end of 2026
Reported positive initial Phase 1a data for RT-114 showing oral bioavailability greater than 150% relative to matched subcutaneous dosing
Completed a $20 million registered direct offering led by a sovereign wealth fund
Entered a new R&D collaboration with PegBio to explore oral delivery of obesity molecules using the RaniPill platform
Appointed Nicholas Maestas as Chief Financial Officer
Appointed Michelle Gilson to the Board of Directors to serve as Chair of the Audit Committee
Cash, cash equivalents, and marketable securities totaled $53.4 million as of June 30, 2026, with funding sufficient through 2027
Contract revenue for the quarter ended June 30, 2026, was $1.7 million driven by the Chugai agreement
Research and development expenses for the quarter were $5.0 million, down from $5.5 million in the prior year period
General and administrative expenses for the quarter were $5.5 million, up from $5.0 million in the prior year period
Net loss for the quarter ended June 30, 2026, was $8.4 million compared to $11.2 million in the same period last year